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Background: Reducing unnecessary antibiotic exposure is a key strategy in reducing the development and
selection of antibiotic-resistant bacteria. Hospital antimicrobial stewardship (AMS) interventions are inherently
complex, often requiring multiple healthcare professionals to change multiple behaviours at multiple timepoints
along the care pathway. Inaction can arise when roles and responsibilities are unclear. A behavioural perspective
can offer insights to maximize the chances of successful implementation.
Objectives: To apply a behavioural framework [the Target Action Context Timing Actors (TACTA) framework] to exist-
ing evidence about hospital AMS interventions to specify which key behavioural aspects of interventions are detailed.
Methods: Randomized controlled trials (RCTs) and interrupted time series (ITS) studies with a focus on reducing
unnecessary exposure to antibiotics were identified from the most recent Cochrane review of interventions to
improve hospital AMS. The TACTA framework was applied to published intervention reports to assess the extent
to which key details were reported about what behaviour should be performed, who is responsible for doing it
andwhen, where, how often andwith whom it should be performed.
Results: The included studies (n= 45; 31 RCTs and 14 ITS studies with 49 outcome measures) reported what
should be done, where and to whom. However, key details were missing about who should act (45%) and when
(22%). Specification of who should act was missing in 79% of 15 interventions to reduce duration of treatment in
continuing-care wards.
Conclusions: The lack of precise specification within AMS interventions limits the generalizability and reproduci-
bility of evidence, hampering efforts to implement AMS interventions in practice.
VC The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the
original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
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Introduction
Reducing unnecessary exposure to antibiotics in hospitals is a key
strategy in reducing the development, selection and spread of
antibiotic-resistant bacteria.1
Many hospitals around the world have implemented antimicro-
bial stewardship (AMS) programmes involving a multidisciplinary
AMS team and a systematic approach for actions to improve
responsible/appropriate antibiotic use.2 Establishing which inter-
ventions are most effective in reducing antibiotic exposure is an
important first step towards improving antibiotic prescribing.
However, identifying AMS interventions that have been successful
in one setting is not enough to ensure effective AMS interventions
will be effectively implemented more widely in hospitals.
The Cochrane review of interventions to improve antibiotic pre-
scribing to hospital inpatients provides clear evidence that AMS
interventions can increase compliance with antibiotic policy.3
There were 221 included studies in the review, with the majority
focusing on choice, route or dose of antibiotic medicines. There
was high-certainty evidence from randomized controlled trials
(RCTs) that AMS interventions can reduce the total duration of
antibiotic treatment and evidence from interrupted time series
(ITS) studies provided additional evidence that the results of AMS
interventions are reproducible in routine practice.3 The aim of this
review is to use a behavioural perspective to examine the AMS
interventions in these RCTs and ITS studies from the Cochrane
review and to make recommendations about the application of
behaviour-change principles to the design and reporting of future
interventions.
Hospital AMS interventions are inherently complex, often
requiring multiple healthcare professionals to change multiple
behaviours at multiple timepoints along the care pathway.
Inaction can arise when roles and responsibilities are unclear.
Effective AMS interventions are more likely to be interpretable, re-
producible and implemented if it is clearly specified what behav-
iour(s) should be performed, who is responsible for doing it and
when, where, how often and with whom it should be performed.4,5
Specifying behaviour in this way is known as the TACTA framework:
Target (patient group, e.g. elective surgery patients), Action (start
or stop antibiotics), Context (specific hospital ward, e.g. surgical
ward), Timing (when to start or stop, e.g. 24 h after surgery)
and Actors (healthcare professionals responsible for the action,
e.g. the surgeon who performed the operation).6 Poor specification
of behaviour creates difficulties for research (hampering interpret-
ation of results, replication of interventions and studies, and
evidence synthesis) and practice (impeding replication, scaling up
and implementation of effective AMS interventions into clinical
settings). Applying TACTA to ensure precise specification of
problems and recommendations makes implementation more
feasible; it provides greater clarity about what is required and
greater certainty about whether it has been accomplished.6,7
Our aim in this study was to apply this framework that guides
specification of behaviours to evidence from the Cochrane review
about interventions focused on reducing unnecessary exposure to
antibiotics3 in order to determine the extent to which stewardship
interventions are currently specified in key behavioural elements
and thereby explore what insights can be gleaned for efforts to
implement AMS interventions in hospitals.
Methods
Study selection
For this review, we included relevant studies from the 196 RCTs and ITS
studies included in the Cochrane review of interventions to improve anti-
biotic prescribing to hospital inpatients.3 Detailed methods of the Cochrane
review are reported elsewhere3 and Figure 1 provides a diagram of study
flow for this review. Studies were included if the prescribing outcome was
coded by the original Cochrane review team as a decision to start or stop
antibiotics, with the intervention target to reduce exposure. We excluded
studies if the target was to increase antibiotic exposure as focusing on
reducing unnecessary exposure to antibiotics in hospitals is a key strategy
in reducing the development and selection of antibiotic-resistant bacteria.
Data extraction
Two authors (E.M.D. and P.G.D.) reviewed the full text of each included
study. We separated the studies into those based in ICUs versus continu-
ing-care wards because ICUs have higher staffing levels with daily rounds
by senior medical staff.8 In contrast, prescribing decisions in continuing-
care wards are more likely to be made by doctors-in-training and there is
increasing evidence about the complex social and professional dynamics
underlying their prescribing decisions.9–11 In the Cochrane review, 51% of
interventions were coded as designed and delivered by a multidisciplinary
Antimicrobial Management Team of physicians working with pharmacists
and/or nurses.3 Details of the AMS interventions were extracted verbatim
from the original studies. Effective Practice and Organisation of Care (EPOC)
Studies from Cochrane review
(n = 221)
Studies screened
(n = 196 RCTs or ITS studies) 149 studies excluded,outcome measured:
choice
(n = 128)
clinical
(n = 3)
microbial
(n = 12)
ming of first dose
(n = 6)
RCTs or ITS studies with
exposure (starng or
stopping anbiocs) as
outcome (n = 47)
Two studies excluded:
target for intervenon:
increase use of
prophylaxis
(n = 2)
Studies included in
qualitave synthesis
(n = 45)
25 studies excluded:
non-RCT or ITS study
(n = 14)
idenfying unintended
consequences
(n = 11)
Figure 1. Study flow diagram.
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intervention categories were included based on the original Cochrane
review coding.3
Behavioural specification
The TACTA framework6 was used to specify verbatim descriptions of the
interventions in terms of Target (patient group), Action (start or stop antibi-
otics), Context (specific hospital ward), Timing (when to start or stop) and
Actors (healthcare professionals responsible for the action). Two authors
(E.M.D. and P.G.D.) independently coded interventions and then compared
coding. Two additional authors (J.J.F. and F.L.) reviewed the final coding.
Differences in coding of each element were resolved by discussion.
Results
Details of included studies
The 45 included studies were 31 RCTs and 14 ITS studies and
reported on 49 outcomes of AMS interventions (4 studies reported
2 outcomes for their interventions12–15). Details of individual stud-
ies are given in Tables S1 to S4 (available as Supplementary data at
JAC Online): country; number of hospitals; context; target patients;
intervention; action; timing; actors; and outcome. The most repre-
sented country setting was the USA (12 studies), followed by
Switzerland (10 studies). Most studies were conducted in a single
country setting, but one was carried out across five countries.16
The maximum number of hospitals within a single study was 41.17
There were 15 interventions to reduce the number of patients who
started antibiotics (Table S1), 4 to reduce duration of antibiotic
prophylaxis (Table S2) and 30 to reduce duration of antibiotic treat-
ment; 16 in ICUs (Table S3) and 14 in continuing-care wards (Table
S4). Four RCTs12–15 measured the effect of an intervention both on
reducing the number of patients who started antibiotics and on
the duration of treatment in patients who started antibiotics.
Five of the EPOC intervention categories18 are reflected in
the included studies: (i) educational outreach through review and
recommendation for change; (ii) audit and feedback about compli-
ance with policies; (iii) dissemination of educational materials;
(iv) reminders; and (v) structural interventions. In addition, one
study included a restrictive intervention.19
Defining clinical behaviours with TACTA
The application of the TACTA framework to coding AMS interven-
tions is demonstrated for two studies20,21 in Table 1 as examples.
Both studies were intended to reduce the duration of antibiotic
prophylaxis for adults undergoing elective surgery. However, there
were important differences with respect to actions, timing and
actors (Table 1). Both studies included AMS interventions with ex-
plicit assignment of responsibility for stopping antibiotics to the
surgeon (actor). However, in one of these studies20 the action was
supported by introducing a default order for prophylactic antibiot-
ics to stop after 24 h and by making pharmacists responsible for re-
view of patients to ensure that antibiotics had been stopped. Both
studies used an ITS design and the results show different effects of
the AMS interventions over time (Figure 2). Both studies improved
performance, but did not reach the target of 95% reliability in the
first 6 months after the AMS interventions started. However, in one
of the studies20 changes were made to the intervention over time;
the Surgical Infection Prevention Team noted remaining room
for improvement and went to the Pharmacy and Therapeutics
Committee to request that it approve an automatic stop on
prophylactic antibiotics after 24 h (48 h for cardiothoracic proce-
dures). Following this approval, pharmacists automatically
stopped administration of prophylactic antibiotics ordered for
more than 24 or 48 h and this was associated with sustained im-
provement to 95% reliability.20 In contrast, there was no change in
the intervention in the other study and the process was still only
60%–70% reliable at 10–12 months post-intervention (Figure 2).21
When the TACTA framework was applied to all studies we
found that the action, context and target patients were always
specified, but specification of timing and actors was more variable
(Table 2).
Actions
Action was specified across all studies included in this review and
three actions were apparent: (i) starting antibiotics; (ii) stopping
prophylactic antibiotics; and (iii) stopping therapeutic antibiotics.
Starting antibiotics
Fifteen studies evaluated interventions relating to starting, or
not starting, antibiotics (Table 2; further details in Table S1).
In 12 of these, the AMS intervention was a reminder linked to a
laboratory test result: procalcitonin in 9 studies,12–15,22–26 rapid
microbiology diagnostic test for viruses or atypical bacteria in 2
studies27,28 and IL-8 in 1 study.16 In three studies, the AMS inter-
vention was the introduction of a guideline about management
of bronchiolitis,17,29,30 with audit and feedback in two of these
studies.29,30
Stopping prophylactic antibiotics
There were four ITS studies of AMS interventions to reduce dur-
ation of prophylactic antibiotics in adult surgical patients (Table 2;
Table 1. Examples of TACTA specification of behaviour for two studies of
interventions intended to reduce duration of antibiotic prophylaxis after
surgery
TACTA
domain Dull et al.20 (2008) Sun et al.21 (2011)
Target adults undergoing elective sur-
gery: coronary artery bypass
graft (CABG); other cardiac
surgery; hip arthroplasty; knee
arthroplasty; colorectal surgery;
hysterectomy; and vascular
surgery
adults undergoing
elective surgery:
CABG
Action stop antibiotics stop antibiotics
Context surgical wards in two hospitals in
the USA
cardiac surgery ward in
one hospital in
Taiwan
Timing 24 h after surgery (48 h after
cardiac surgery)
24 h after surgery
Actors surgeon who performed the oper-
ation and pharmacists
cardiac surgeon
Duncan et al.
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Table 2. Number of studies that specified target, action, context, timing and actors
Action Context Studies (design) Target patients Timing Actors
Starting
antibiotics
emergency
department
9 (6 RCT12,13,22,25,26,28,
3 ITS17,29,30)
8 community-acquired LRTI, 1
fever
9 on admission 3 resident, supervised, 3
treating physician, 3 not
clear
ward 6 (6 RCT14–16,23,24,27) 3 community-acquired LRTI, 1
acute exacerbation of
asthma, 1 community-
acquired fever in neonates,
1 post-cardiac surgery
5 on admission, 1 after
surgery
5 treating physician, 1
physician in charge
Stopping
prophylactic
antibiotics
operating
theatre
2 (2 ITS31,32) 2 elective surgery 2 at start of operation 2 not clear
surgical ward 2 (2 ITS20,21) 2 elective surgery 2 at 24 h post-operative 1 pharmacist and surgeon,
1 surgeon
Stopping
therapeutic
antibiotics
ICU 16 (14 RCT19,33–45,
2 ITS46,47)
8 sepsis, 5 hospital-acquired
LRTI, 3 all on antibiotics
9 multiple (e.g. daily)
reviews, 2 single re-
view (e.g. at 48–72 h),
5 not clear
6 treating physician, 2
physician in charge, 1
one of four ICU consul-
tants, 1 AMT member, 6
not clear
ward 14 (9 RCT12–15,49,51,55–57,
5 ITS48,50,52–54)
6 all on antibiotics, 5 commu-
nity-acquired LRTI, 1 posi-
tive blood cultures, 1 acute
pancreatitis, 1 acute
exacerbations of pulmon-
ary fibrosis
3 multiple (e.g. daily)
reviews, 5 single re-
view (e.g. at 48–72 h),
6 not clear
3 treating physician,
11 not clear
LRTI, lower respiratory tract infection; AMT, Antimicrobial Management Team.
Note that the total number of studies is 49 because 4 RCTs12–15 measured the effect of an intervention on two actions (starting and stopping antibiot-
ic treatment) with different outcome measures for each action.
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Figure 2. Intervention effect over time for two studies that aimed to increase the percentage of patients who received surgical antibiotic prophylaxis
for24 h. Drawn from data reported by Dull et al.20 (2008) and Sun et al.21 (2011).
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further details in Table S2). The interventions were audit and
feedback in three studies20,21,31 and a new guideline in one.32
Stopping therapeutic antibiotics
There were 16 studies of AMS interventions to reduce duration of
antibiotic treatment in ICUs (Table 2; details in Table S3), introduc-
tion of procalcitonin testing in 11 studies,33–43 review of prescribed
antibiotics by members of the AMS team in 4 studies19,44–46
and introduction of a new guideline in one study.47 There were 14
studies of AMS interventions on duration of antibiotic treatment
in inpatient wards (Table 2; details in Table S4), including review
and recommendation for change by a member of the AMS team
in 5 studies,48–52 antibiotic guidelines in 2 studies53,54 and rapid
microbiology testing in 1 study.55 Procalcitonin featured in six
studies.12–15,56,57
Context
Context was specified across all the studies included in this review
and included emergency departments (in 9 studies), operating
theatres (in 2 studies), surgical wards (in 2 studies), ICUs (in 16
studies) and wards (in 20 studies).
Target
The target patients for AMS interventions were specified across all
the studies and included patients with community-acquired lower
respiratory tract infection (in 16 studies), all patients (in 9 studies),
patients with sepsis (in 8 studies), patients with hospital-acquired
lower respiratory tract infection (in 5 studies), elective surgical
patients (in 4 studies), patients with fever (in 1 study), neonatal
patients with community-acquired fever (in 1 study), post-cardiac
surgical patients (in 1 study), patients with positive blood cultures
(in 1 study), patients with acute pancreatitis (in 1 study) and
patients with acute exacerbations of pulmonary fibrosis (in 1
study).
Timing
Overall, the timing of when an intervention should occur was
specified in 76% of studies. Timing was specified for all interven-
tions that targeted starting antibiotics or stopping prophylactic
antibiotics. However, timing of interventions to stop therapeutic
antibiotic treatment was specified for only 11 (69%) of 16 studies
in ICUs and 7 (50%) of 14 studies in wards (Table 2).
Actors
Overall, the actor of an intervention was specified in 55% of the
studies. Actors were specified for 12 (80%) of 15 AMS interventions
targeted at starting antibiotics, but only for 2 (50%) of 4 AMS inter-
ventions targeted at stopping prophylactic antibiotics. Actors were
specified in 10 (63%) of 16 ICU studies and 3 (21%) of 14 ward
studies where AMS interventions were to stop antibiotic treatment
(Table 2). Three of the interventions targeted at starting antibiotics
specified that the actor was a resident who was supervised by a
senior physician12,13,22 and two of the interventions targeted at
stopping antibiotics in ICUs specified that the actor was one of
four ICU consultants46 or the member of the Antimicrobial
Management Team (AMT) who reviewed the patient.19 In contrast,
several studies specified actors as either the ‘treating physician’ or
‘physician in charge’ (Table 2), terms that do not clarify the role of
junior and senior doctors or the clinical speciality.
Summary of results
When the TACTA framework was applied to all studies we found
that the action, context and target were always specified.
Emergency departments were the context for 60% of interven-
tions targeting patients who start treatment and ICUs were the
context for 56% targeting duration of treatment. Procalcitonin
was the most common AMS intervention overall. Specification of
timing and actors was less reliable, particularly for AMS interven-
tions targeting antibiotic treatment in wards.
Discussion
The key finding in this review is that studies did not consistently re-
port the actor (who is responsible) and timing (when to start/stop
antibiotics), whilst target (patient group), action (what should be
done) and context (where, e.g. ward or unit) were always specified.
Decision-making about antimicrobial use in hospitals is a complex
process, which can involve one or more actors and be influenced
by cultural factors such as etiquette and hierarchy.58–61 Few AMS
interventions included in this review specified more than one actor
and only one specified an actor who was not a doctor,20 which fails
to reflect the multi-professional care-delivery system of antibiotics
in hospitals.9,10,62–65
Defining clinical behaviours with the TACTA framework
The first step in a behavioural approach to designing (and report-
ing) interventions is to define the problem in behavioural terms:
who needs to do what differently to whom, where and when? The
second step is to identify and prioritize a range of potential target
behaviours.4 Poor specification of the target behaviour, as this re-
view has found for AMS interventions, causes problems for both re-
search (creating difficulties for interpreting results, replication of
interventions and studies, and evidence synthesis) and practice
(impeding replication, scaling up and implementation of effective
AMS interventions into clinical settings). Two of the AMS interven-
tions to stop prophylactic antibiotics identified the surgeon as an
actor for their intervention and made them specifically responsible
for the action20,21 (Table 1). Both interventions improved perform-
ance, but did not reach the target of 95% reliability within
6 months. In one study the AMS intervention was revised, which
was associated with sustained improvement to 95% reliability20
(Figure 2). Iterative review should be the rule rather than the ex-
ception in behaviour-change interventions, with revision of the
intervention if it is not achieving its goal or if it has unanticipated,
unpleasant consequences.66–68 However, the study by Dull et al.20
was the only example, among 45 included studies, of review and
revision of an intervention through identification of additional
actors.
In comparison with stopping therapeutic antibiotics, changing
behaviour to stop prophylactic antibiotics may be more straightfor-
ward for two reasons. First, there is compelling evidence that stop-
ping prophylactic antibiotics after 24 h does not increase risk of
surgical site infection and that continuing antibiotics for >24 h is
Duncan et al.
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likely to increase risk of Clostridioides difficile infection,69 which can
be used to influence prescribers’ motivation through beliefs about
consequences. Second, the patients are undergoing elective
surgery, which facilitates the opportunity to clearly identify both
the target and the actors for the intervention.
All of the included studies described the physical context for the
intervention as either ICUs or continuing-care wards (Table 1). In
ICUs, daily rounds by senior doctors are the norm8 and most AMS
programmes already include review by infection specialists.2,70,71
In contrast, in continuing-care wards, regular review of patients is
often done by doctors-in-training, supported by less frequent ward
rounds by senior doctors.9–11,61 A realist review of evidence from
131 studies found that doctors-in-training operate within chal-
lenging contexts (hierarchical relationships, powerful prescribing
norms, unclear roles and responsibilities) where they prioritize
particular responses due to fear of criticism and fear of individual
responsibility for patients deteriorating.11 The authors conclude
that these complex dynamics explain how and why doctors-in-
training follow senior clinicians’ prescribing habits, take into
account advice from other health professionals, ask questions or
challenge decisions.11 Furthermore, two recent qualitative studies
found that the social context in which doctors-in-training work can
be very different in medical and surgical wards.58,61 There is
already evidence about differences in professional identity and
culture between medicine and surgery, but these studies demon-
strate the need for a thorough understanding of specialty-specific
norms surrounding antimicrobial prescribing.72
Only three of our included studies explicitly identified doctors-
in-training as actors and described their supervision by senior
colleagues.12,13,22 All three of these studies were from emergency
departments. In contrast, of the five studies of AMS interventions
to stop antibiotics in continuing-care wards through review
by a member of the AMS team, only two identified an actor for
the recommendation and both of these were ambiguous.
Recommendations through ‘direct interaction with the prescribing
physician’51 or through communication ‘to the clinician caring for
the child’52 could be interpreted as either for the junior doctor who
wrote the prescription or reviews the patient regularly, or as the se-
nior doctor who is responsible for the patient. In the remaining
three studies, the recommendation was entered into the medical
record48,49 or was communicated ‘by telephone, through the
electronic medical record or on rounds’50 so it was not clear who
was expected to act on the recommendation.
Hospital AMS interventions focused on reducing
exposure to antibiotics
Procalcitonin was the most common intervention focused on ex-
posure overall, accounting for half of the studies targeting patients
who start antibiotics on admission to hospital and the duration of
therapeutic antibiotics in wards (Table S1), with the majority of
studies targeting duration of therapeutic antibiotics in ICUs (Table
S3). In 2015, NICE issued guidance on procalcitonin testing for two
indications: stopping antibiotic treatment in people with confirmed
or highly suspected sepsis in the ICU, or starting and stopping
antibiotic treatment in people with suspected bacterial infection
presenting to the emergency department.70 The guidance was
based on evidence from a systematic review of 18 studies, which
included 12 RCTs from our review.12,13,15,25,26,33,34,36–38,43,57
NICE did not recommend adoption of procalcitonin because the
control arm in these RCTs did not reflect current standard clinical
practice in the UK. We believe that the same concerns apply to
five studies from our review that were not included in the NICE
guidance.14,22–24,56
In 2015, a survey about AMS in 421 hospitals from Asia, Africa,
Europe, North America, Oceania and South America reported that
testing for procalcitonin or other inflammatory markers was used
to influence decisions about starting or stopping antibiotics in only
36% of hospitals.2 In contrast, the majority of these hospitals used
the other AMS interventions from our review: dissemination of
guidelines (94%), review and recommendation for change in anti-
biotic therapy through telephone consultation (89%) or ward
rounds (81%), audit (80%) and review of patients with bacter-
aemia (73%).
There are strengths and limitations to this review to consider. It
is a review of studies included within an existing review rather than
a systematic review of primary studies. This means that there may
have been recently published AMS intervention studies that were
not included in the Cochrane review and it is possible that recently
conducted studies of AMS interventions have been reported more
precisely in published reports. A strength of this review is in the ap-
plication of an existing behavioural framework, TACTA, which has
an established track record of application to reports of interven-
tions6 and a grounding in behavioural theory.73 Other frameworks
exist to encourage thorough descriptions of interventions and aid
replication of studies, such as the TIDieR checklist.74 However, the
TIDieR checklist is focused on reporting of the details of interven-
tion elements within a study rather than clearly specifying the
behaviours that need to change as a result of the intervention. A
behavioural approach using TACTA can add to reporting guidelines
like TIDieR by increasing clarity and helping to operationalize the
intervention elements themselves.75
Conclusions
The evidence that we have reviewed shows that actors and timing
are poorly defined in AMS interventions to reduce unnecessary
antibiotic prescribing in hospitals. This lack of specification is likely
to hamper efforts to replicate successful interventions, synthesize
evidence and implement successful interventions into practice.
This lack of specification is particularly true for review of antibiotic
treatment in continuing-care wards, where changing professional
behaviour to influence antibiotic use is likely to be particularly chal-
lenging. There is a growing number of examples of theory-driven,
systematic approaches to intervention design.76,77 However, there
is still a need to improve definition of problems in behavioural
terms and improve understanding of current behaviour in context
in order to maximize learning through evidence synthesis and
detailed intervention reporting.77 Studies reporting AMS interven-
tions to reduce unnecessary antibiotic prescribing in hospitals
should consider applying a behavioural framework to ensure that
the evidence they provide can be used to help to build a picture of
what works and that the what, who, when, where, how often and
with whom of effective interventions can be operationalized into
practice.
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